Third, in a humanized CRC PDX model established by Capasso et al., treatment with nivolumab, a fully human IgG4 (S228P) monoclonal antibody to PD-1, led to significant tumor growth inhibition coupled with increased numbers of IFNγ-producing human CD8+ tumor-infiltrating lymphocytes [123]. Here, CD8A is linked to neoplasm.